Amgen CEO Robert Bradway scored a 5.8% increase in overall compensation last year mostly thanks to the company’s acquisition of Horizon Therapeutics.
House Oversight Committee Chair James Comer (R-KY) sent a stern letter to FTC chair Lina Khan last week, claiming the commission improperly disclosed confidential information as it reviewed the merger between Amgen and Horizon Therapeutics, which was completed in early October.
For 10 months, the biopharma industry waited to see if Amgen and Horizon Therapeutics would prevail in their $27.8 billion merger following scrutiny and challenges from the FTC and other government leaders.
THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
Rule 17(e) Announcement - Horizon Therapeutics plc
Rule 17(d) Announcement – Horizon Therapeutics plc
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)